Get the Stockscreener App
1.82
8.77%
-0.175
After Hours:
1.81
-0.01
-0.55%
Adlai Nortye Ltd Adr stock is traded at $1.82, with a volume of 83,914.
It is down -8.77% in the last 24 hours and down -1.09% over the past month.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
See More
Previous Close:
$1.995
Open:
$1.78
24h Volume:
83,914
Relative Volume:
5.83
Market Cap:
$170.55M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-0.7223
EPS:
-2.5197
Net Cash Flow:
-
1W Performance:
-1.62%
1M Performance:
-1.09%
6M Performance:
-18.39%
1Y Performance:
-76.36%
1-Day Range:
$1.78
$1.96
1-Week Range:
$1.78
$2.10
52-Week Range:
$1.10
$8.37
Adlai Nortye Ltd Adr Stock (ANL) Company Profile
Compare ANL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANL
Adlai Nortye Ltd Adr
|
1.82 | 68.27M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.85 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.16 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.52 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Adlai Nortye Ltd Adr Stock (ANL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
Adlai Nortye Ltd Adr Stock (ANL) Latest News
Adlai Nortye Discontinues Buparlisib Development After Phase III Trial Results - TipRanks
ANL stock touches 52-week low at $1.71 amid sharp annual decline - Investing.com India
ANL stock touches 52-week low at $1.71 amid sharp annual decline By Investing.com - Investing.com South Africa
ANL stock touches 52-week low at $1.85 amid sharp annual decline By Investing.com - Investing.com South Africa
ANL stock touches 52-week low at $1.85 amid sharp annual decline - Investing.com India
Adlai Nortye stock hits 52-week low at $1.85 amid sharp decline By Investing.com - Investing.com South Africa
Adlai Nortye stock hits 52-week low at $1.85 amid sharp decline - Investing.com India
Adlai Nortye Announces Change in Auditing Firm - TipRanks
Adlai Nortye Announces CFO Transition with Interim Appointment - TipRanks
Trump Announces Nomination of Howard Lutnick to Serve as US Commerce Secretary, to Run Office of US Trade Representative - AASTOCKS.com
Adlai Nortye (ANL) Stock Price, News & Analysis - MarketBeat
Adlai Nortye IPO gives old Novartis cancer drug new life - BioPharma Dive
CRVO Stock Quote Price and Forecast - CNN
Adlai Nortye Ltd Adr Stock (ANL) Financials Data
There is no financial data for Adlai Nortye Ltd Adr (ANL). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.89%
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):